I
IsoPlexis
Powerful Biology Accelerating the Future of Medicine
About IsoPlexis
IsoPlexis is a biotechnology company specializing in single cell proteomics, providing advanced tools for immune medicine research. The company serves clients in the pharmaceutical, biotech, and medical center sectors, focusing on therapies and diagnostics based on biologics and the immune system. IsoPlexis operates in the global healthcare market, offering an all-in-one, intuitive system that fits on any lab bench, known as the IsoLight system. This system detects the most potent cells secreting multiple cytokines at high intensity, providing unique insights unattainable with other systems. IsoPlexis generates revenue through the sale of its proprietary IsoLight system and related consumables, as well as through strategic partnerships and collaborations with industry leaders. The company's business model is centered around providing high-value, cutting-edge technology that accelerates research and improves patient outcomes.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Branford, United States
- Employees
- 42
- Open positions
- None listed
- Dealroom signal
- 67.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Microfluidics, Immune System, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Technology
- Big Data, Deep Tech
- Client focus
- b2b
- Investment activity
- 1 company
- Capital deployed
- —
- Preferred round
- Unknown
Latest news
Press, funding announcements and product moves mentioning IsoPlexis.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Mar 2023 | $0 | — | Berkeley Lights | ↗ |
| IPOOther financing | Oct 2021 | $125M | $125M | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for IsoPlexis is 40 monthly website visits, down 98% over the last three months. IsoPlexis's team declined 4.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed4 investors entered at this stage
- YFYEI Innovation Fund
Connecticut Innovations
National Cancer Institute SBIR Development Center
National Institute on Aging
Series A2 investors entered at this stage
Spring Mountain Capital
Ironwood Capital
Series B and later5 investors entered at this stage
Advantage Capital
Northpond Ventures
BlackRock
Ally Bridge Group
Perceptive Advisors
Other known investors2 additional known investors
Berkeley Lights
Yale University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about IsoPlexis on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IsoPlexis’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.